Author, as appears in the article.: Pérez-Cantero A, Serrano DR, Navarro-Rodríguez P, Schätzlein AG, Uchegbu IF, Torrado JJ, Capilla J

Department: Ciències Mèdiques Bàsiques

URV's Author/s: Capilla Luque, Javier / PÉREZ CANTERO, ALBA

Keywords: Supplementation Shiitake Resistance Posaconazole Oral delivery Necrosis-factor-alpha Molecular envelope technology Lipid nanoparticles Lentinula edodes Lentinan Hexose-correlated compound Fungus Fumigatus Formulations Chitosan Aspergillosis Amphotericin b Ahcc® Ahcc (r)

Abstract: Invasive pulmonary aspergillosis represents one of the most serious fungal infections among immunocompromised patients. In this study, we aimed to analyze the in vivo efficacy of prophylactic oral amphotericin B (AMB) encapsulated in modified chitosan-nanoparticles (Nanomerics' Molecular Envelope Technology (MET)) supplemented with a standardized extract of cultured Lentinula edodes mycelia (AHCC®) in a murine model of pulmonary aspergillosis. We determined fungal burden and survival of mice and additionally, we carried out a cytokine analysis in an attempt to understand the immunomodulation of the extract. Our results evidenced equivalent efficacy between orally administered AMB-MET and the intravenous liposomal AMB marketed formulation. Addition of the AHCC® supplement significantly improved efficacy in terms of burden reduction and survival increase of both oral and intravenous AMB therapies compared to the untreated control group. Moreover, a protective effect of the extract was observed in terms of weight loss. Regarding the cytokine profiles, the Th1 immune response was stimulated in treated animals when compared to the control group. This response was marked by an enhancement in the MCP-1, GM-CSF, VEGF, RANTES and IL-17 levels and a decrease in the IL-6, a biomarker related to the severity of the infection.

Thematic Areas: Pharmacology & pharmacy Pharmaceutical science Medicina ii Farmacia Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología

licence for use: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 19994923

Author's mail: javier.capilla@urv.cat

Author identifier: 0000-0002-0765-6403

Record's date: 2023-02-18

Journal volume: 11

Papper version: info:eu-repo/semantics/publishedVersion

Link to the original source: https://www.mdpi.com/1999-4923/11/9/456

Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/

Papper original source: Pharmaceutics. 11 (9):

APA: Pérez-Cantero A, Serrano DR, Navarro-Rodríguez P, Schätzlein AG, Uchegbu IF, Torrado JJ, Capilla J (2019). Increased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCC® Natural Adjuvant against Aspergillosis. Pharmaceutics, 11(9), -. DOI: 10.3390/pharmaceutics11090456

Article's DOI: 10.3390/pharmaceutics11090456

Entity: Universitat Rovira i Virgili

Journal publication year: 2019

Publication Type: Journal Publications